Clinicopathological characteristics

Overall survival (n = 364)

Progression-free survival (n = 366)

N

Hazard ratio

P-value

N

Hazard ratio

P-value

Stage

1

170

1.97 (1.06~3.66)

0.0285

170

2.14 (1.29~3.57)

0.0027

1 + 2

253

1.79 (1.11~2.91)

0.0162

254

1.79 (1.21~2.65)

0.0031

2

83

2.05 (0.93~4.5)

0.0687

84

0.53 (0.27~1.03)

0.0565

2 + 3

166

2.33 (1.4~3.88)

0.0008

167

0.83 (0.55~1.23)

0.3481

3

83

2.98 (1.55~5.72)

0.0006

167

1.36 (0.75~2.47)

0.3068

3 + 4

87

2.6 (1.41~4.77)

0.0014

88

1.41 (0.79~2.51)

0.2415

Grade

1

55

3.5 (1.35~9.03)

0.0062

55

2.06 (0.91~4.68)

0.0767

2

174

2.81 (1.37~5.74)

0.0031

175

2 (1.29~3.09)

0.0015

3

118

3.19 (1.73~5.87)

8.8e~5

119

1.41 (0.82~2.42)

0.2128

4

12

-

-

12

-

-

AJCC-T

1

180

1.99 (1.1~3.59)

8.8e~5

180

2.18 (1.33~3.59)

0.0016

2

90

1.86 (0.88~3.94)

0.1003

92

0.55 (0.29~1.04)

0.0622

3

78

2.2 (1.18~4.1)

0.0115

78

0.78 (0.43~1.41)

0.4175

4

13

-

-

13

-

-

Vascular invasion

none

203

2.03 (1.22~3.4)

0.0057

204

2.07 (1.31~3.27)

0.0015

micro

90

1.95 (0.87~4.38)

0.1006

91

0.55 (0.29~1.08)

0.0769

macro

16

-

-

16

-

-

Gender

Male

246

2.04 (1.3~3.19)

0.0015

246

1.69 (1.17~2.44)

0.0048

Female

118

2.42 (1.38~4.26)

0.0015

120

1.74 (1~3.03)

0.0454

Race

white

181

1.29 (0.79~2.12)

0.3044

183

1.31 (0.85~2.04)

0.2234

Black or African american

17

-

-

17

-

-

asian

155

4.83 (2.32~10.06)

3.4e~6

155

2.92 (1.67~5.1)

8.6e-5

Sorafenib treatment

treated

29

2.34 (0.7~7.81)

0.154

30

2.51 (1.05~0.6)

0.0335

Alcohol consumption

yes

115

2.13 (1.14~3.99)

0.0152

115

1.63 (0.92~2.88)

0.0928

none

202

2.12 (1.3~3.46)

0.002

204

2.35 (1.5~3.7)

0.0001

Hepatitis Virus

yes

150

2.08 (1.07~4.05)

0.0279

152

1.76 (1.09~2.86)

0.02

none

167

2.35 (1.49~3.7)

0.0001

167

2.01 (1.3~3.13)

0.0015